Antares Pharma, Inc. (AIS) Reports In-Line Q4 EPS

Antares Pharma, Inc. (NYSE: AIS) reported Q4 EPS of $0.00, in-line with the analyst estimate of $0.00. Revenue for the quarter came in at $5.4 million versus the consensus estimate of $4.88 million.

For earnings history and earnings-related data on Antares Pharma, Inc. (AIS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Forgent Power Solutions jumps as Bernstein sees massive earnings upside
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M